Hemolytic Disease

In the second part of an interview about nutrition for fertility, two experts discussed nutrition and other lifestyle considerations for women with polycystic ovary syndrome trying to conceive.

Postnatal treatment approaches to hemolytic disease of the fetus and newborn vary significantly worldwide, highlighting the need for better practice agreements to improve care, according to results of a cohort study.

Nipocalimab resulted in more live births at 32 weeks’ gestation or later without fetal anemia or intrauterine transfusion for pregnancies at risk for early-onset severe hemolytic disease of the fetus and newborn, researchers reported.

Extending routine donor-recipient matching to include Rhesus c, E and K antigens was tied to lower odds for hemolytic disease of the fetus and newborn vs. standard ABO blood type and Rhesus D antigen matching, researchers reported.

Cell-free DNA analyses were accurate in detecting fetal antigen status as early as 10 weeks’ gestation in women with alloimmunized pregnancies, according to results of a large, diverse U.S. cohort study published in Obstetrics & Gynecology.